p53 and β-catenin expression predict poorer prognosis in patients with anaplastic large cell lymphoma

Publication date: Available online 5 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aida Ibricevic Richardson, C. Cameron Yin, Wei Cui, Nianyi Li, L. Jeffrey Medeiros, Linheng Li, Da ZhangAbstractThe Wnt/β-catenin signaling pathway is a major target of p53. β-catenin/p53 co-expression predicts poorer survival in carcinoma patients. Conversely, CD99 inhibits tumor metastasis through Wnt/β-catenin pathway. We therefore assessed p53, β-catenin and CD99 by immunohistochemistry in 45 patients with systemic anaplastic large cell lymphoma (ALCL), including 20 anaplastic lymphoma kinase (ALK) positive and 25 ALK-negative ALCL. β-catenin expression was analyzed using phospho-β-catenin-S552 antibody since its nuclear localization indicates Wnt signaling. In this cohort, p53 expression was associated with ALK-negative ALCL. Furthermore, p53 or β-catenin expression alone or β-catenin/p53 double-expression showed poorer overall survival and disease-free survival in patients with ALCL overall and in patients with ALK-negative ALCL. CD99 expression was more frequent in ALK-positive ALCL but had no prognostic significance. This is the first study to evaluate phospho-β-catenin-S552 expression in ALCL. The results of this study, although limited by small patient size, suggest that β-catenin and p53 may play a role in pathogenesis and may be helpful in risk stratification of ALCL patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research